{"classes":[{"categories":[{"measurements":[{"comment":"BLQ","groupId":"OG000","lowerLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"1","value":"1"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"77.58","value":"26.533"},{"groupId":"OG003","lowerLimit":"4.92","upperLimit":"8.03","value":"6.407"},{"groupId":"OG004","lowerLimit":"0.97","upperLimit":"25.37","value":"5.778"},{"groupId":"OG005","lowerLimit":"0.95","upperLimit":"5.05","value":"2.340"},{"groupId":"OG006","lowerLimit":"1.50","upperLimit":"48.60","value":"8.720"},{"groupId":"OG007","lowerLimit":"1.53","upperLimit":"8.58","value":"3.13"},{"groupId":"OG008","lowerLimit":"1.53","upperLimit":"1.7","value":"1.587"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"9"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Flat dose level; 0.15mg (Dose Level 1)","id":"OG000","title":"Part A Dose Level 1 NM21-1480-Q2W 0.15mg"},{"description":"Flat dose level; 1.5mg (Dose Level 2)","id":"OG001","title":"Part A Dose Level 2 NM21-1480-Q2W 1.5mg"},{"description":"Flat dose level; 8mg (Dose Level 3)","id":"OG002","title":"Part A Dose Level 3 NM21-1480-Q2W 8mg"},{"description":"Flat dose level; 24mg (Dose Level 4)","id":"OG003","title":"Part A Dose Level 4 NM21-1480-Q2W 24mg"},{"description":"Flat dose level; 80mg (Dose Level 5)","id":"OG004","title":"Part A Dose Level 5 NM21-1480-Q2W 80mg"},{"description":"Flat dose level; 240mg (Dose Level 6)","id":"OG005","title":"Part A Dose Level 6 NM21-1480-Q2W 240mg"},{"description":"Flat dose level; mg800 (Dose Level 7)","id":"OG006","title":"Part A Dose Level 7 NM21-1480-Q2W 800mg"},{"description":"This part of the study consisted of a 1400mg flat dose across one cohort.","id":"OG007","title":"Part A2 NM21-1480-Q2W"},{"description":"This part of the study consisted of a 800mg flat dose across three cohorts.","id":"OG008","title":"Part B NM21-1480-Q2W"}],"paramType":"MEAN","populationDescription":"Tmax determined at C1 for all dose levels with the exception of Part A Dose Level 1 and Part A Dose Level 2. Lower limit of quantification (LLOQ) of NM21-1480 = 5 ng/mL.","reportingStatus":"POSTED","timeFrame":"From baseline to up to 12 weeks post last dose, up to 48 weeks.","title":"Assessment of the Time From Dosing at Which Cmax is Apparent Determined by Direct Inspection of the Concentration Versus Time Data (Tmax)","type":"SECONDARY","unitOfMeasure":"h"}